n: 41) for patients with overdose. In 66%, a risk factor of overdose was identified: age 75 years (63%), comorbidity (15% like diabetes). The median cost of PCC treatment was a888/patient (a592-a888) representing 9.3% of the total hospitalisation cost paid by national health insurance for those 91 patients. CONCLUSIONS: PCC was used according to the recommendations and in respect of the health care regulations for reimbursement. The high increase of prescription observed in 2008, mainly in the emergency department (48%), can be explained by a change of medical practices and prescribing behaviour since the new recommendations.
PSY57

REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA-PHARMACOECONOMICS OF USTEKINUMAB IN PSORIASIS
Tomek D 1 , Bielik J 2 1 Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 2 Trencin University, Trencin, Slovak Republic OBJECTIVES: Although health spending is well below the OECD average when considered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of total health care budget. The accessibility and availability of innovative drugs is good. Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH set the official threshold by l1 l1 1 a18,000/QALY and l2 l2 2 a26,500/QALY. METHODS: We have analysed the legislation and official reimbursement decisions and commentaries, published by the MoH in 2009. We analysed the applicants documentation including pharmacoeconomic analysis, as a mandatory part of the application.
RESULTS:
The main drug reimbursement body-Categorisation committee of the MoH and pharmacoeconomic advisory committee evaluated the applicants dossier for the biologic drug ustekinumb (Stelara®, Jannssen Cilag Slovakia) for the treatment of psoriasis. The pharmacoeconomic part of the application fulfiled all legislative aspects. The CEA shows that ustekinumab is more cost effective in cost of theraphy responder analysis vs. other biologics in the Slovak market for psoriasis treatment by 2%-60%. The price sensitivity analysis of comparators was done. The reassessment of CEA after massive price cut of comparators (up to 32%, due to international price referencing) has showed the positive results for ustekinumab and robustness of previous price sensitivity analysis. CONCLUSIONS: The focus of the MoH drug policy is on more rational spendings , especially on reference pricing and HTA. There are first results of these new procedures, where the real impact of the HTA in the decision processes is demonstrated. Ustekinumb a new agent in therapy of psoriasis fulfilled the necessary legislative conditions including pharamacoeconomic aspects to be listed in the positive reimbursement list.
PSY58 RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE
Linder R 1 , Olsson Birgersson M 2 , de Faire U 3 , Ridderstråle M 4 , Rössner S 3 , Sjöström L 5 , Rydén L 3 1 Pygargus AB, Stockholm, Sweden, 2 sanofi aventis AB, Stockholm, Sweden, 3 Karolinska Institutet, Stockholm, Sweden, 4 University Hospital MAS, Malmö, Sweden, 5 Sahlgrenska University Hospital, Gothenburg, Sweden OBJECTIVES: To describe the prescription pattern of rimonabant in relation to the approved indications and the stated limitations of reimbursement. Secondly to compare the efficiency and adverse effects in rimonabant treated patients with the impact of conventional care in matched controls without rimonabant treatment during a follow up period of up to 12 months. METHODS: The survey was based on retrospective collection of data through a specified extraction and data management method, Pygargus Customized eXtraction Program (CXP) developed to extract patient data from an Electronic Health Record (EHR) system (Profdoc Journal III). Centers were selected with a wide socio-economic and geographical spread. RESULTS: Body mass index (BMI) was available in 922 patients out of 1477 (62%). Of those patients, 93% were prescribed rimonabant according to the indication and 79% within the reimbursement criteria. In reality, 97% of the total cohort obtained reimbursement. Patients prescribed rimonabant for at least 6 months showed a mean weight reduction of 6.0 kg after 12 months compared to 0.4 kg in controls. The mean decrease in HbA1c was 0.3% in patients with type-2 diabetes versus 0.0% in controls. More than half of patients and controls (54.4 vs. 54.3 %) had a documented psychiatric illness such as anxiety, depressive disorders or sleep disturbances at baseline. There was no increase in the co-prescription of anxiolytics /sedatives /anti-depressant over time comparing rimonabant treated patients with controls. CONCLUSIONS: The majority of patients were prescribed rimonabant according to the given rules for indication and reimbursement. Weight reduction in the total cohort and reduction of HbA1c in patients with type 2 diabetes during the follow up year, were of similar magnitude as reported in various clinical trials. The safety analysis did not signal any increase in adverse events including psychiatric illness in patients treated with rimonabant more than six months.
PSY59 REVIEW OF RECOMMENDATIONS OF HEALTH TECHNOLOGY ASSESSMENTS ON ORLISTAT AND SIBUTRAMINE
Jensen RCØ 1 , Adalsteinsson E 1 , Toumi M 2 , Hemels M 1 1 Novo Nordisk A/S, Søborg, Denmark, 2 University Claude Bernard Lyon I, Villeurbanne Cedex, France OBJECTIVES: To review recommendations of Health Technology Assessment (HTA) reports on sibutramine and orlistat in the treatment of obesity from France (HAS), UK (NICE), Sweden (TLV), Belgium (KCE) and Canada (CADTH). METHODS: HTA reports were identified by searching each HTA agency's homepages using "sibutramine" OR "orlistat" as keywords. Results were categorised as Recommended, Restricted recommended and Not Recommended in comparison to the indication for marketing authorisation given by EMEA. RESULTS: A total of eleven HTA reports were identified; six assessing orlistat and five sibutramine. Four HTA-reports on orlistat gave a positive recommendation while the remaining HTA reports did not recommend use/funding. Reasons for not recommending orlistat included; insufficient data to quantify obesity-related morbidity and mortality, uncertainties in compliance due to side effects, treatment effect was not maintained after discontinuation, lack of long term safety data, and poor definition of indication "metabolic syndrome". For sibutramine, three reports concluded Recommended, one Restricted recommended and one Not recommended. Reasons for a negative and restricted recommendation included; insufficient data to quantify obesity-related morbidity and mortality, and lack of long term safety data. CONCLUSIONS: Quantity of effect of weight loss on morbidity and mortality, defining an appropriate indication for initiating pharmacological treatment and adequate provision of data on long-term safety and effectiveness appears to be main issues driving a negative recommendation. These issues must be addressed in the development of a clinical documentation of future pharmacological treatments of obesity. It is interesting to notice that similar evidences lead to very It is interesting to notice that similar evidences lead to very contradictory outcome reflecting broader way to scrutinize evidences for HTA decision making.
POSTER SESSION III CONCEPTUAL PAPERS & RESEARCH ON METHODS -Clinical Outcomes Methods
PMC1 CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH
Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 2 Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 3 Tufts-New England Medical Center, Boston, MA, USA OBJECTIVES: To clarify how the standard estimate of incremental cost-effectiveness ratio (ICER) theoretically changes, affected by the uncertainty accompanied with statistical errors and probability of truth in evidence-based practice, and further to investigate how the 'risk'-adjusted ICER (r-ICER) could be used in the analysis of efficiency frontier by IQWiG. METHODS: A decision analysis was performed using: 1) probability of truth, 1 -p, for a null hypothesis (or p for the alternative hypothesis), 2) type I error ( ), and 3) type II error ( ).The decision tree modeled a patient facing the alternative decisions for treatment: evidence-based (Teb) or conventional (Tc), considering the choices: 1) Tc: if no evidence available about a new treatment A, then the patient takes a conventional treatment B, and 2) Teb: if positive evidence of a clinical trial available, then take the treatment A, whereas if the evidence is negative, take the treatment B. Given a pair of benefit and cost for the treatments A and B, respectively noted as (Ea, Ca) and (Eb, Cb) at the terminal node, then the operations
